Literature DB >> 34053578

The Role of Fibroblast Activation Protein Ligands in Oncologic PET Imaging.

Katharina Dendl1, Joel Schlittenhardt1, Fabian Staudinger1, Clemens Kratochwil1, Anette Altmann2, Uwe Haberkorn2, Frederik L Giesel3.   

Abstract

Fibroblast activation protein inhibitor emerges as a novel and highly promising agent for diagnostic and possibly theranostic application in various malignant and non-malignant diseases. FAPI impresses with its selective expression in several pathologies, ligand induced internalization, and presence in a large variety of malignancies. Current studies indicate that FAPI is equal or even superior to the current standard oncological tracer fluorodeoxyglucose in several oncological diseases. It seems to present lower background activity, stronger uptake in tumorous lesions and thus sharper contrasts. For improved comprehension of fibroblast activation, protein expression and clinicopathologic conditions, further studies are of essence.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer-associated fibroblasts; FAP; FAPI PET/CT; Fibroblast activation protein; Small molecule inhibitors

Year:  2021        PMID: 34053578     DOI: 10.1016/j.cpet.2021.03.012

Source DB:  PubMed          Journal:  PET Clin        ISSN: 1556-8598


  5 in total

1.  Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [18F]F-FDG in Oncology: A Systematic Review.

Authors:  Giorgio Treglia; Barbara Muoio; Hessamoddin Roustaei; Zahra Kiamanesh; Kamran Aryana; Ramin Sadeghi
Journal:  Int J Mol Sci       Date:  2021-10-17       Impact factor: 5.923

2.  Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor-Directed Molecular Imaging and Therapy.

Authors:  Sebastian E Serfling; Philipp E Hartrampf; Yingjun Zhi; Takahiro Higuchi; Steven P Rowe; Lena Bundschuh; Markus Essler; Andreas K Buck; Ralph Alexander Bundschuh; Rudolf A Werner
Journal:  Clin Nucl Med       Date:  2022-04-19       Impact factor: 10.782

3.  Head-to-head Intra-individual Comparison of [68Ga]-FAPI and [18F]-FDG PET/CT in Patients with Bladder Cancer.

Authors:  E Novruzov; K Dendl; H Ndlovu; P L Choyke; M Dabir; M Beu; F Novruzov; E Mehdi; F Guliyev; S A Koerber; I Lawal; G Niegisch; J Debus; U Haberkorn; M Sathekge; F L Giesel
Journal:  Mol Imaging Biol       Date:  2022-03-29       Impact factor: 3.484

4.  Characteristics of tumour stroma in regional lymph node metastases in colorectal cancer patients: a theoretical framework for future diagnostic imaging with FAPI PET/CT.

Authors:  Petur Snaebjornsson; Wilma E Mesker; Meaghan Polack; Sophie C Hagenaars; Alice Couwenberg; Walter Kool; Rob A E M Tollenaar; Wouter V Vogel
Journal:  Clin Transl Oncol       Date:  2022-04-28       Impact factor: 3.340

5.  From Automated Synthesis to In Vivo Application in Multiple Types of Cancer-Clinical Results with [68Ga]Ga-DATA5m.SA.FAPi.

Authors:  Lukas Greifenstein; Carsten S Kramer; Euy Sung Moon; Frank Rösch; Andre Klega; Christian Landvogt; Corinna Müller; Richard P Baum
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.